Dissertations / Theses on the topic 'CNS drugs'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'CNS drugs.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Kyles, Andrew Edward. "Evaluation of the spinal and supraspinal roles of antinociceptive drugs in sheep." Thesis, University of Bristol, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389998.
Full textRahman, Shazia. "Use of (2S)-pyroglutamic acid for the synthesis of glutamate agonists and antagonists and 1-#beta#-methylcarbapenams." Thesis, University of Sussex, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.264581.
Full textSekhar, Gayathri Nair. "The transport of CNS-active cationic drugs across the blood-brain barrier." Thesis, King's College London (University of London), 2016. https://kclpure.kcl.ac.uk/portal/en/theses/the-transport-of-cnsactive-cationic-drugs-across-the-bloodbrain-barrier(41ff27df-17ce-4edc-82fe-c4169edf801c).html.
Full textLloyd, Edward John, and mikewood@deakin edu au. "A common structural basis for central nervous system drug design." Deakin University. School of Biological Sciences, 1986. http://tux.lib.deakin.edu.au./adt-VDU/public/adt-VDU20050902.115505.
Full textBerggård, Cecilia. "Transcription Factor AP-2 in Relation to Personality and Antidepressant Drugs." Doctoral thesis, Uppsala University, Department of Neuroscience, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4638.
Full textThe CNS monoaminergic systems are considered as the head engine regulating neuropsychiatric functions and personality. Transcription factor AP-2 is known to be essential for the development of the brainstem including the monoaminergic nuclei, and has the ability to regulate many genes in the monoaminergic systems. The ability of transcription factors to regulate specific gene expression, has lately made them hot candidates as drug targets. In this thesis, results indicating a role of AP-2 in the molecular effects of the antidepressant drugs citalopram and phenelzine, are presented.
A polymorphism in the second intron of the gene encoding AP-2ß has previously been associated with anxiety-related personality traits as estimated by the Karolinska Scales of Personality (KSP). In this thesis, results confirming this association, gained by using a larger material and several different personality scales, are presented. Furthermore, data is presented showing an association between the activity of platelet monoamine oxidase, a trait-dependent marker for personality, and the genotype of the AP-2ß intron 2 polymorphism.
The functional importance of the AP-2ß intron 2 polymorphism has not yet been elucidated. Included in this thesis are results showing that the AP-2ß intron 2 polymorphism is not in linkage disequilibrium with the only other described polymorphism in the AP-2ß gene, i.e. in the AP-2ß promoter (-67 G/A). Introns have in several studies been shown to include binding sites for regulatory proteins, and thus, to be important in transcriptional regulation. Results are presented demonstrating that one human brain nuclear protein binds only to the long variant of the AP-2ß intron 2 polymorphism. If this protein is involved in the regulation of the AP-2ß gene, it would affect the expression levels of the AP-2ß protein.
In general, this thesis further establishes the role of transcription factor AP-2 as a regulatory factor of importance for personality and monoaminergic functions.
Patel, Sulay H. "Effects of HIV-1 Tat and drugs of abuse on antiretroviral penetration inside different CNS cell types." VCU Scholars Compass, 2018. https://scholarscompass.vcu.edu/etd/5685.
Full textGarcia-Mijares, Miriam. "Efeito da administração aguda e repetida de fencanfamina sobre o valor reforçado do estímulo." Universidade de São Paulo, 2000. http://www.teses.usp.br/teses/disponiveis/47/47135/tde-14092006-114120/.
Full textFencanfamina (FCF) is an indirect dopaminergic agonist with neural and behavioral effects similar to those observed for other stimulant drugs such as the amphetamine or cocaine (COC). The aim of the present investigation was to evaluate the effect of acute and repeated administration of FCF on the reinforcing value (Re) taken as a motivational index. The Herrnstein hyperbole equation (1970) was used to evaluate this motivacional effect. The effects of FCF on response rate and motor capacity (k) where also observed. Three experiments were conducted. In all of them the effect of FCF was tested on rats trained on seven VI multiple schedule. In Experiments 1 and 2 (E1 and E2, respectively) three acute doses of FCF (0.88 mg/kg, 1.75 mg/kg and 3.5 mg/kg) were administered (i.p.) The reinforcer was water (E1) or sacarose (E2). In both experiments, the effect of the drug on the parameters studied was similar: the three doses of FCF increased the response rate, decreased Re and had no effect on k. In Experiment 3, six injections of vehicle (VEI Group) or 1.75 mg/kg of FCF (DROGA Group) were intermittently administered (i.p.) in order to promote sensitization. Seven days after drug withdrawal a single dose of 0.88 mg/kg of FCF was administered to animals in both groups and the effect on response rate, k and Re was measured. Results showed that repeated administration of FCF did not change the effect of this drug on the parameters investigated. These results are consistent with the evidence showing that FCF has behavioral effects similar to those reported for other stimulants and support the interpretation that increases in response rate are primarily related to changes in reinforcing value. Thus they probably reflect a motivational effect of the drug. Moreover, the results support the hypotheses that associate the dopaminergic system to the process of reinforcement. It is speculate that the failure to obtain sensitization after repeated administration of FCF could be related to dosage or number of injections.
Mercolini, Laura <1979>. "Development of original analytical methods for the therapeutic drug monitoring of CNS druges: Antipsychotics, Antidepressants and Anxiolytics-hypnotics." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2010. http://amsdottorato.unibo.it/2713/.
Full textJain, Anjana. "Delivery of Cdc42, Rac1, and Brain-derived Neurotrophic Factor to Promote Axonal Outgrowth After Spinal Cord Injury." Diss., Georgia Institute of Technology, 2007. http://hdl.handle.net/1853/16210.
Full textFidanboylu, Mehmet. "Blood-CNS transport mechanisms in pathophysiology and drug delivery." Thesis, King's College London (University of London), 2013. https://kclpure.kcl.ac.uk/portal/en/theses/bloodcns-transport-mechanisms-in-pathophysiology-and-drug-delivery(2081d984-07fe-41aa-9f5b-54d1f33be9f2).html.
Full textArora, Priyanka. "Pharmacokinetic- Pharmacodynamic Investigations of Letrozole, a Potential Novel Agent for the Treatment of High-Grade Gliomas." University of Cincinnati / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1552398989110981.
Full textSvensson, Åsa. "Application of a New Logic to Old Drugs: Angiogenesis Inhibition in Neuroblastoma." Doctoral thesis, Uppsala University, Department of Medical Cell Biology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3458.
Full textNeuroblastoma is one of the most common solid cancers of early childhood. In Sweden, approximately 10-15 cases occur annually. The overall five-year neuroblastoma survival in Europe is approximately 45%. Since cancer treatment involves drugs with risks of side effects in the growing child, there is a need for more effective and less toxic drugs. One new approach in cancer treatment is inhibition of tumor angiogenesis, i.e., of new blood vessel growth into the tumor. An angiogenesis inhibitor may be combined with cytostatic drugs to enhance the efficacy. The aim of this study was to investigate how drugs could be used to inhibit angiogenesis and tumor growth in a xenograft model of human neuroblastoma in nude mice.
The tumors express the angiogenesis stimulator vascular endothelial growth factor (VEGF) on both protein and mRNA levels. The angiogenesis inhibitors SU5416 (an inhibitor of VEGF signalling) and TNP-470 (an inhibitor of endothelial cell proliferation) inhibited angiogenesis in our model. TNP-470, however, inhibited angiogenesis without significant reduction of the tumor growth, in contrast to SU5416.
We also discovered that the cytostatic drug CHS 828 could cause regression of neuroblastoma tumors in the model when given orally at a low daily dose, alone or in combination with the angiogenesis inhibitor SU5416 or TNP-470.
Furthermore, a new use of the cardiac glycoside digoxin was found. Digoxin inhibited FGF-2 -stimulated bovine capillary endothelial cell growth in vitro, and inhibited angiogenesis in vivo in the chick chorioallantoic membrane assay (CAM). It also inhibited neuroblastoma growth by approximately 50% in our neuroblastoma model.
In conclusion, CHS 828 and digoxin represent two classes of drugs with potent antitumor effects that may be valuable in treatment of neuroblastoma, either alone or in combination with angiogenesis inhibitors.
Ball, Kathryn. "Physiologically based pharmacokinetic modelling of the central nervous system : strategies for drug development." Thesis, Paris 5, 2014. http://www.theses.fr/2014PA05P630.
Full textA critical step during drug development is the measurement or the prediction of drug concentrations in the target tissue, which can then be linked to measures of drug efficacy or toxicity. Drug concentrations cannot be directly measured in the human brain, and must be simulated or predicted using alternative modeling approaches. The objective of this thesis is to develop in silico approaches to predict BBB penetration of drugs, combining in vitro and in vivo preclinical data in a physiologically structured model, with a translational strategy to allow the simulation of total and free drug concentrations in the human brain. Physiologically based pharmacokinetic (PBPK) models were developed and evaluated for reference molecules already on the market, as well as for a drug currently under clinical development within the pharmaceutical industry. These models were developed based on both ‘bottom-up’ (model parameter values predicted from in vitro data) and ‘top-down’ (model parameters estimated from in vivo data) strategies. This thesis is comprised of 5 scientific papers which are either published or submitted to peer-reviewed journals. The first article is a review of the literature, published in the AAPS journal. This review discusses the currently published PBPK models available for the mechanistic prediction of BBB penetration of drugs, and proposes a strategy for in vitro-in vivo (IVIVE) extrapolation. The second article is an original research article published in Molecular Pharmaceutics. This article aims to show the development of a coherent pharmacokinetic modeling approach in the rat which can be adapted based on the quantity and quality of data obtained in vivo during the development of new drugs. A decision tree was constructed to enable the appropriate parameterization and model structure based on the available data. The third article is an original research article published in Journal of Pharmaceutical Sciences. This article was based on the development of a PBPK model for the mechanistic prediction of BBB penetration of drugs, in which the active and passive components of permeability were considered separately, as well as the intra-brain tissue binding parameters. An in vitro-in vivo strategy was proposed to extrapolate the active transport component using a relative activity factor (RAF) to account for in vitro-in vivo differences in transporter activity and/or abundance. Two additional articles are either submitted or under preparation. These articles extend the PBPK approaches described in the previous two published original research articles. The final part of this thesis consists of a discussion which emphasizes clearly the importance of the appropriate choice of modeling approach, or even better, a combination of approaches based on physiological knowledge, experimental data and knowledge gathered during the course of drug development. The advantage of mechanistic parameterization of PBPK models is the improved ability for inter-species extrapolation for the subsequent simulation of free or total drug concentrations within the human brain. This thesis has considerably contributed to this rapidly evolving field of CNS drug research and development, showing the importance of combining in vitro and in vivo data within a physiologically based model structure, thus providing a valuable tool for the quantitative prediction of the penetration of drugs in the human brain
Hassan, Saadia Bashir. "Methods for Preclinical Evaluation of Cytotoxic Drugs : With Special Reference to the Cyanoguanidine CHS 828 and Hollow Fiber Method." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4696.
Full textOswald, Mira [Verfasser], and Achim [Akademischer Betreuer] Göpferich. "Targeted CNS Delivery via Nanoparticulate Drug Delivery Systems / Mira Oswald ; Betreuer: Achim Göpferich." Regensburg : Universitätsbibliothek Regensburg, 2017. http://d-nb.info/1139170708/34.
Full textSahm, Ulrike Gisela. "Interaction of naturally occurring and synthetic MSH peptides with peripheral and CNS melanocortin receptors." Thesis, University of Bath, 1994. https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.385312.
Full textO'Rourke, Catriona. "Development of novel, robust 3D CNS tissue models for neurobiological studies and drug discovery." Thesis, Open University, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.700133.
Full textEkelund, Sara. "Microphysiometry in the evaluation of cytotoxic drugs with special emphasis on the novel cyanoguanidine CHS 828." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2001. http://publications.uu.se/theses/91-554-5105-5/.
Full textÅleskog, Anna. "Application of In Vitro Chemosensitivity Testing for Evaluation of New Cytotoxic Drugs in Chronic Lymphocytic Leukaemia." Doctoral thesis, Uppsala University, Department of Medical Sciences, 2002. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3073.
Full textDespite major advances in the understanding of the biology of chronic lymphocytic leukaemia (CLL), progress in improving its treatment has been limited and it still remains an incurable disorder. In the present research, we have performed in vitro drug sensitivity testing of primary CLL cells for preclinical evaluation of cytotoxic drugs, using the fluorometric microculture cytotoxicity assay (FMCA).
The tumour type-specific activities of 14 standard drugs, evaluated in vitro on tumour cells from patients with CLL and acute leukaemias, were in good agreement with their known clinical activities. A correlation between drug treatment and development of cellular drug resistance was demonstrated in CLL, but not in the acute leukaemias. Moreover, the nucleoside analogues fludarabine, cladribine, cytarabine and gemcitabine, as well as the anthracycline idarubicin, were highly active in CLL cells.
A new cytotoxic drug candidate, CHS 828, was evaluated in primary cell cultures from a broad spectrum of tumours. CHS 828 was highly active against haematological malignancies in vitro, especially CLL, but also against some solid tumours. The drug appeared to be non cross-resistant with standard drugs.
In addition, the relationship between drug sensitivity in vitro and a recently described prognostic factor in CLL, the mutational status of the immunoglobulin variable heavy chain (IgVH) gene, was evaluated. Interestingly, cells with unmutated IgVH genes were more chemosensitive than the mutated cells.
In summary, our results indicate that in vitro studies on tumour cellsfrom leukaemia patients may yield considerable information regarding the activity, mechanisms of action and cross-resistance of cytotoxic drugs, as well as concerning the relationship between drug sensitivity and prognostic factors, which can be useful in the preclinical evaluation of new cytotoxic drugs. Furthermore, the results suggest that the pyrimidine analogues cytarabine and gemcitabine, as well as the anthracycline idarubicin, may have a role in the treatment of CLL. The new cyanoguanidine CHS 828 is highly active in CLL cells and appears to be non cross-resistant with standard drugs. The poorer prognosis in patients with CLL cells with unmutated IgVH genes can not be explained by increased chemoresistance.
Gulmez, Sinem. "EPIHAM Drug-induced liver injury leading to hospital admission : a study in national healthcare insurance databases." Thesis, Bordeaux, 2017. http://www.theses.fr/2017BORD0592.
Full textThe main objective of EPIHAM study is to identify the main drugs associated with drug induced liver injury leading to hospital admission (DILIH) in France and the event rates associated with DILIH. Three methodological approaches were defined. Principal approach is case-population. The others are case-crossover and case control analyses. Cases were identified among adult patients present in SNIIRAM database having a first hospitalization between 01/01/2010-2010/31/12/1204, the main diagnosis of which is toxic liver disease (diagnostic codes according to the International Classification of Diseases (ICD-10) K71.1, K71.2, K71.6, K71.9) orK72.0. Reference population was defined from the EGB. Index date (ID) was considered as the date of hospital admission for DILI. The dispensations of all treatments preceding the ID were studied by considering an exposure windowvarying from 7 to 60 days before ID. The most frequently found are classical: analgesics and firstly paracetamol, followed by drugs acting on digestive system (proton pump inhibitors, prokinetics, antispasmodics). The following were amoxicillinalone or combined with clavulanic acid, ibuprofen, codeine combinations, and furosemide. These results can inform health authorities, practitioners and patients about the acute hepatitis risk leading to hospitalisation associated with each of these molecules, both individually (absolute risk, attributable risk) and within a therapeutic drug family (relative risk) as well as more generally for the population and the health system (absolute number of attributable cases)
Miron, Veronique. "The effects of CNS-accessible multiple sclerosis-directed immuno-modulatory therapies on oligodendroglial lineage cells, myelin maintenance, and remyelination /." Thesis, McGill University, 2008. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=115701.
Full textStatins inhibit the production of cholesterol (concentrated in the myelin membrane) and isoprenoids (post-translational attachments regulating the functions of proteins such as the Rho GTPases). We showed that treatment of human and rodent-derived OPCs with lipophilic statins induced an initial process extension associated with enhanced differentiation and impaired spontaneous migration, whereas prolonged treatment induced process retraction and cell death. Rodent and human mature OLGs demonstrated similar cytoskeletal and survival responses. Chronic simvastatin therapy of mice inhibited remyelination following demyelination induced by the OLG toxin, cuprizone, attributed to a block in OPC differentiation and consequent decrease in mature OLGs. Even fully myelinated animals treated with simvastatin over the long-term demonstrated a decrease in myelin in the brain by maintaining oligodendroglial cells in the pre-OLG state and preventing continual replacement of mature OLGs.
FTY720 is an agonist of G-protein-coupled receptors S1P1, 3, 4, and 5, that are associated with distinct receptor isotype-selective activation of Rho GTPases. In human OPCs, FTY720 could induce initial S1P3/5-dependent process retraction associated with an inhibition of differentiation, and subsequent S1P1-dependent process extension. Mature OLGs showed a dose-dependent cyclic modulation of process extension and retraction was observed over time. Both human OPCs and OLGs were rescued by FTY720 under death-promoting environments. Both cell types also demonstrated a cyclic and reciprocal modulation of S1P1 and S1P5 mRNA levels, reflected in the recurring receptor isotype-dependent functional responses over time. Studies using organotypic cerebellar slice cultures demonstrated that FTY720 did not impact myelin integrity under basal conditions, yet accelerated remyelination following lysolecithin-induced demyelination. Both treatment regimens were associated with an extension of OPC and mature OLG processes.
Our observations demonstrate that drug concentrations used to modulate immune function can have differential dose and time-dependent effects on OPCs, OLGs, as well as on myelin and remyelination processes. Our findings indicate the need to monitor the effects of putative immuno-modulatory therapies on myelin-related processes in MS patients.
Duffett, Rodger Vincent. "The effect of cis-platinum alone or in combination with radiation on mouse lung." Master's thesis, University of Cape Town, 1999. http://hdl.handle.net/11427/26352.
Full textBoehm, Michael. "EXPERIMENTAL INVESTIGATION OF TWO-PHASE PENETRATING FLOW OF NEWTONIAN AND NON-NEWTONIAN POLYMERIC FLUIDS AND DEVELOPMENT OF PRACTICAL APPLICATIONS IN DRUG/GENE DELIVERY." The Ohio State University, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=osu1253548237.
Full textHovstadius, Peter. "Preclinical and Clinical Development of the Novel Cyanoguanidine CHS 828 for Cancer Treatment." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6178.
Full textKoukpo, Rachel Sainhoundé. "Le droit des produits de santé en Afrique de l'Ouest : le cas du Bénin et du Sénégal." Thesis, Bordeaux 4, 2012. http://www.theses.fr/2012BOR40008/document.
Full textDrugs are a particular consumer product having a multiple purposes. Specific goods carryrisks in themselves, and shouldn’t be distributed solely to the mainstream market. Rather, theymust be evaluated before, during and after their commercial life. Active products arenecessary for healthcare, but contain numerous risks. The entire cycle (production, delivery,recovery) of all health products must be very strictly supervised and entrusted to aprofessional’s responsibility. Their supervision therefore requires the attention of the wholehealth care community, and must be strictly regulated because health problems can resultfrom misuse. These features of the drug involve a certain codification system. Regulatoryrequirements govern the place on the market and use of these assets to ensure their quality,effectiveness and safety. Medical malpractice is not always well supervised in the medicaland hospital atmosphere of Africa. And in case of damage to health resulting from misuse, itis important to consider the rights and responsibilities of the various people involved(healthcare professionals, patients, government). Medical errors cannot be prevented if theculture of risk and responsibility is not instilled in the minds of the public. This is aprerequisite for the reorganisation of the distribution of health products
Alterman, Julia F. "A CNS-Active siRNA Chemical Scaffold for the Treatment of Neurodegenerative Diseases." eScholarship@UMMS, 2019. https://escholarship.umassmed.edu/gsbs_diss/1027.
Full textDjenna, Abdallah. "Brevet et développement : le cas de l'Algérie." Thesis, Grenoble, 2013. http://www.theses.fr/2013GREND004.
Full textThe logic of the new international economic system is based on the idea that the patent is a legal mechanism to incentive research and development. The subject of our study is to know if the variations of the levels of development among between different countries could affect the function of the patent in the third world. In this perspective, we have to analyze the Algerian patent law and the changes they have undergone in order to adapt to the high level of protection required by the international system in order to examine the effects of the requirement of these conditions on reveal developments. Then we analyzed the Algerian regime of patents and the changes it has undergone in order to adapt to the level of protection required by the international system, to examine the effects of these requirements on you development. That the patent system in Algeria fulfills its universal function as an instrument for incentive technological innovation and development, several changes in the legal, institutional and economic should be performed
Cowie, Philip David. "Analysis of the effects of disease-associated variation within a cis-regulatory element of the CNR1 locus on CNR1 promoter dynamics." Thesis, University of Aberdeen, 2014. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=225652.
Full textFrost, Britt-Marie. "Chemotherapy in Childhood Acute Lymphoblastic Leukemia : In vitro cellular drug resistance and pharmacokinetics." Doctoral thesis, Uppsala University, Department of Women's and Children's Health, 2002. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2664.
Full textThe aims of the studies described in this thesis were to investigate the pharmacokinetics of and cellular resistance to chemotherapy as causes of treatment failure in childhood acute lymphoblastic leukemia (ALL).
Leukemic cells from 370 children with newly diagnosed ALL were tested by the Fluorometric Microculture Cytotoxicity Assay to measure their resistance to each of ten standard cytotoxic drugs. In the high-risk group, increased in vitro resistance to each of the drugs dexamethasone, etoposide and doxorubicin was associated with a worse clinical outcome. Combining the results for these drugs yielded a drug resistance score, showing a relative risk of relapse in the most resistant group that was 9.8 times higher than in the most sensitive group. In the standard-risk and intermediate-risk groups, final evaluation must await longer follow-up.
The new cytotoxic agent CHS 828 was equally active in vitro in samples from children with acute myeloblastic leukemia (AML) and ALL, with 50% cell kill at concentrations achievable in vivo. In AML samples CHS 828 also displayed high frequencies of synergistic interactions with four standard drugs. The well-known differences in clinical outcome between Down´s syndrome (DS) and non-DS children with acute leukemia may partly be explained by our finding of differences in drug resistance at the cellular level.
Pharmacokinetic studies were performed at the start of induction treatment of ALL. Doxorubicin was assayed by reversed-phase liquid chromatography with fluorometric detection, and vincristine by high performance liquid chromatography with electrochemical detection. Plasma doxorubicin concentrations were measured in 107 children after 23 h of a 24-h infusion. The median steady-state concentration in children 4-6 years old, a group known to have a favorable outcome of treatment, was about 50% higher than in those 1-2 and >6 years old Vincristine pharmacokinetics was evaluated in 98 children. There was no correlation between age and total body clearance or any other pharmacokinetic parameters.
In vitro testing of cellular drug resistance might be useful in predicting the outcome in high-risk ALL. The further exploration of CHS 828 in childhood leukemia seems warranted. There is no pharmacokinetic rationale for the common practice of administering relatively lower doses of vincristine to adolescents than to younger children.
Sherwood, Alexander M. "Design, Synthesis and Biological Evaluation of Novel Compounds with CNS-Activity Targeting Cannabinoid and Biogenic Amine Receptors." ScholarWorks@UNO, 2014. http://scholarworks.uno.edu/td/1831.
Full textNsarhaza, Bishikwabo Kizito. "La restructuration du secteur de santé et le marché informel: cas de la République Démocratique du Congo." Doctoral thesis, Universite Libre de Bruxelles, 1997. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/212128.
Full textLittle, James L., Curtis D. Cleven, and Stacy D. Brown. "Identification of “Known Unknowns” Utilizing Accurate Mass Data and Chemical Abstracts Service Databases." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etsu-works/5300.
Full textPinto, Alexandre. "Common scaffolds for the enantioselective synthesis of marine, plant, and amphibian cis-decahydroquinoline alkaloids." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/457969.
Full textRobert, i. Sabaté Laia. "Creació d’un instrument de verificació i guiatge per millorar la qualitat informativa en la comunicació farmacoterapèutica. Cas pràctic amb els inhibidors de la bomba de protons." Doctoral thesis, Universitat de Barcelona, 2020. http://hdl.handle.net/10803/671211.
Full textHealth communication and improving health literacy are key issues in healthcare policies. Treatment benefits and success depend not only on the efficacy of the drug, but also on the patient's knowledge about medicines and his or her level of health literacy. Nowadays, sources of medicines information available to patients are many and varied, but not all of them are of high quality and reliable. Currently, many actors can communicate and disseminate information about medicines, for example healthcare professionals, journalists, healthcare organizations, communication experts or anyone on an individual basis. All of them share the responsibility to guarantee and provide accurate medicines information. The aim of this work is to create a methodology to evaluate and improve the informative quality of subjects related to medicines and pharmacotherapy. This methodology will help to improve the degree of health literacy from the society and it is intended to be used by different agents involved in pharmacotherapeutic communication. To accomplish this, quality and readability of written information about medicines published on an institutional website has been analyzed. A second study of the quality and readability of all the written information that a patient may receive about a group of drugs of widespread use such as PPI (leaflet, official or sources of reference, news and internet information) has been carried out. In this second study, patients taken PPI have also been interviewed in order to know their information’s needs about drugs. Although results in readability are positive, the margin for improvement in quality of the documents not classified as reference one’s (internet information, news .) is wide. What matters most to patients is drug safety and drug effectiveness and they think that medicine’s’ leaflets have too much information, are long and not easy to read. From data of the two performed studies and from a solid literature review, it is proposed a new instrument that will allow to verify the quality of written information about medicines, and at the same time, to guide through the elaboration process. This instrument consists of 10 items: benefits, risks, therapeutic alternatives, effects on quality of life, scientific evidence, bibliography and complementary sources, supporting information, authorship, publication date and plain language. With this instrument, agents involved in the pharmacotherapeutic communication will have a new tool to control and improve the quality of their written information.
Amonkou, Anne Cinthia. "Les bases législatives et réglementaires du développement de l'industrie pharmaceutique en Afrique : le cas de la Côte d'Ivoire." Thesis, Strasbourg, 2018. http://www.theses.fr/2018STRAJ115/document.
Full textA strong local pharmaceutical industry is one of the foundations of an effective health system. The aim of this work was to contribute to the optimization of the legal framework for the development of the pharmaceutical industry. Starting from a description of the legislative and regulatory texts applicable to the pharmaceutical industry in Côte d'Ivoire, we have researched and analyzed the factors that condition the development of this sector of activity and finally formulated axes of optimization. The Ivorian legal corpus on the pharmaceutical industry in force defines an organized normative, institutional and professional framework. The opening of the capital to the non-pharmacists by the legislation of 2015 is to be welcomed. However, genuine promotion measures for the establishment of pharmaceutical laboratories and some protection of the market should be adopted to support the first steps of development of the sector. The political will and ambition of the players in the sector are paramount. Coordination of legal mechanisms through an attractive policy will make it possible to meet the challenge of pharmaceutical industrialization
Roux, Perrine. "Observance thérapeutique des patients multitraités : le cas de la toxicomanie." Thesis, Aix-Marseille 2, 2010. http://www.theses.fr/2010AIX20651/document.
Full textThe epidemic of Human Immunodeficiency Virus (HIV) has profoundly changed the relationship between medicine and humans and vice versa. On the one hand, the intense stigmatization associated with HIV infection has made the disease more complex than for any other pathology. On the other hand, the chronicization of infection has forced care providers to investigate in greater detail the intimate relationship between patient and treatment, and more particularly, the therapeutic adherence. My research work aimed to investigate this latter argument in greater detail, favoring a less paternalistic approach toward therapeutic adherence in HIV-infected patients and applying this approach to multi-treated populations with comorbidities such as drug dependence and hepatitis C. Through several articles, we tried to put in evidence that a model of care that includes patient’s perception about care may lead to better understand non-adherence to treatment (ongoing drug use, drug injection or treatment diversion). In fact, injection cessation or reduction of opioid consumption in dependent individuals is a non-linear process which could take a long time, and which is often punctuated with relapse. Our findings showed the positive impact of access to adequate care to treat not only the disease but also the harm related to non adherence to treatment. The idea is to promote a more deliberative relationship between physician and patient, including a harm reduction approach
Rojas, Diana. "Les transformations de l´intervention à l'ère de la mondialisation : le cas des Etats-Unis en Colombie (1961-2010)." Thesis, Paris Est, 2012. http://www.theses.fr/2012PEST0055/document.
Full textThis research project emerges from an interest in understanding and explaining the interaction between domestic and international politics in the processes of state-building in less developed countries that also have histories of strong3foreign dependence. The main objective of this work is to study the transformation of the phenomena of foreign intervention in the context of globalization through the analysis of the Colombian case. Thus, theories from the discipline of international relations that study intervention as part of the dynamics of contemporary international politics are examined first. Specifically, the intervention related to statebuilding, which is presented in the context of American foreign policy in the 20th century, is analyzed. Second, the intervention of the United States in Colombia in three different periods is explored: the Alliance for Progress (1961-1972), the War on Drugs (1975-1994) and Plan Colombia (2000-2010). Throughout these periods, this study establishes how the intervention of this superpower in this South American country was changing in both its conception and implementation for half of a century. Also, by a detailed examination, the study identifies points of comparison in order to assess whether or not the intervention was oriented towards statebuilding
Constant, Chloé. "Trajectoires et dynamiques carcérales au féminin. Le cas de Lima." Phd thesis, Paris 3, 2013. http://tel.archives-ouvertes.fr/tel-00979203.
Full textMartin, Benoît. "La production des statistiques internationales : le cas de l'Office des Nations unies contre la drogue et le crime (UNODC)." Thesis, Paris, Institut d'études politiques, 2018. http://www.theses.fr/2018IEPP0030.
Full textHow do international organizations produce their statistics? This thesis unveils these singular activities from the case of the United Nations Office on Drugs and Crime (UNODC). The demon-stration follows a double sociological approach (of international relations and of quantification) based on interviews conducted at headquarters (in Vienna, Austria), methodological literature (internal and published) and UN documents (normative and analytical). Quantifying internationally is a complex process organized in successive steps: agreeing a mandate, defining a method, collecting and then processing and validating the data, and finally publishing a world report. The enterprise is collective, involving the UNODC secretariat, member states and experts. However, the task is unequally distributed, the international civil servants realizes or coordinates a large part of the work; just as the interactions between actors are asymmetrical, UNODC depends on its member states in many respects and has no real power to constrain them. Bureaucratic, political, financial and even self-censorship issues affect routine statistical work. In addition, official but administrative national sources – with their documented and delicate biases to overcome – remain mostly used because of their legitimacy. The use of satellite imagery and field surveys is an exception. Developed under such conditions, UN drug and crime statistics provide a more consensual international inventory than the so-called global diagnosis
Pirson, Magali. "Apports de la comptabilité analytique par cas et par pathologie à la gestion hospitalière." Doctoral thesis, Universite Libre de Bruxelles, 2006. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/210867.
Full textLes DRGs représentent la tentative la plus récente de maîtriser la croissance des dépenses des hôpitaux en introduisant une médicalisation partielle des mécanismes de financement.
La connaissance des coûts des pathologies peut permettre aux hôpitaux de participer à l’élaboration des tarifs par pathologie en faisant partie d’un échantillon de référence des coûts hospitaliers. En cas de financement basé sur les pathologies, les hôpitaux doivent pouvoir comparer le coût des séjours au chiffre d’affaires octroyé et s’y adapter. Cet intérêt s’accroît en cas de financement forfaitaire, évolution qui semble se profiler en Belgique tout comme dans d’autres pays. En décrivant une méthodologie de calcul des coûts par pathologie et en indiquant la manière dont ceux-ci pourraient contribuer à la création d’une échelle de cost-weights, notre thèse incite les hôpitaux à adopter une politique proactive dans le domaine du financement des hôpitaux.
Les comparaisons de coûts hospitaliers pour évaluer la gestion sont pratiquées depuis de nombreuses années. Cependant, ce « benchmarking » est imparfait car il ne prend pas en compte la lourdeur des patients pris en charge. La standardisation des coûts sur base du case-mix de l’hôpital suppose un préalable important :l’existence d’une échelle de cost-weights issue d’un échantillon représentatif d’hôpitaux. Si cette situation n’est pas encore totalement rencontrée en Belgique, il est néanmoins possible de suggérer une voie de réflexion. La simulation inspirée de la méthodologie suisse à partir d’un échantillon de quatre hôpitaux belges présentée dans le cadre de cette thèse, est une première avancée en ce sens.
Un des problèmes majeurs de la gestion hospitalière est d’intéresser les prescripteurs et les prestataires à un contrôle de gestion essentiellement financier. Depuis quelques années, de nombreux efforts visent à intégrer de nouveaux indicateurs de performance dans les tableaux de bord. L’analyse des coûts des pathologies et de la variabilité des cas permet d’entamer un dialogue entre gestionnaire et corps médical. En abordant différentes études (apport des nomenclatures dans le calcul des coûts par pathologie, mesure des coûts associés aux bactériémies nosocomiales, analyse des facteurs médico-sociaux expliquant les surcoûts des patients outliers, analyse de la relation entre le coût et la sévérité des cas, comparaison des coûts de production et des pratiques médicales), nous avons voulu montrer l’importance d’associer une approche médicalisée à des raisonnements économiques. Si elle se développe, cette approche est susceptible de représenter un moyen de communication idéal entre le personnel médical et soignant et le monde de la gestion.
Comme nous le rappelions au début de cette thèse, les concepteurs des DRGs (Fetter et Thompson) ont regretté le manque d'intérêt manifesté par les gestionnaires d'hôpitaux pour l'utilisation de leur concept dans le management hospitalier. Au terme de cette thèse, nous pensons que, si l'analyse des coûts par pathologie reste encore d'un abord difficile, elle peut rendre d'importants services en associant médecins et managers à l'élaboration d'un contrôle de gestion enfin adapté à la spécificité de leurs institutions.
Doctorat en Sciences de la santé publique
info:eu-repo/semantics/nonPublished
Ferchakhi, Widiane. "Influence du risque percu sur l'intention d'achat d un produit générique : le cas du médicament." Thesis, Lyon, 2016. http://www.theses.fr/2016LYSE3070.
Full textThis thesis aims to understand the obstacles to the purchase of generic drugs in patients-consumers. More specifically, it aims, through a qualitative and a quantitative study, to improve the efficiency of communication of health actors to reduce the perceived risk in buying generics. More precisely, it intends to examine the variables that explain the patients-consumers attitudes towards the substitution, to understand the mechanisms involved in this process and to highlight the most likely variables that explain the intention of purchasing a generic (vs brand name) drug. Thus, we aimed to explore the factors that explain the perception and reduction of risks towards the generic drugs by conducting individual semi-structured interviews with 24 patients-consumers. The results of the quantitative study of 303 individuals point out that (1) the perceived risk towards the substitution and the attitude towards generic drugs mediate the relationship between the perceived risk towards generic drugs and attitude towards substitution, (2) the trust in the information source (pharmacist and physician) moderates the relationship between the attitude towards substitution and the intention of purchasing a generic (vs brand name) drug and (3) the interaction effect between the brand equity of generic drug : low (vs strong ), the chronicity of disease : non chronic (vs chronic) and the repayment rate : 65% (vs 100%) on the intention purchase generic (vs brand name) drug is validated. Theoretically, the research sheds light on the literature on the perceived risk in health, including mobilizing a concept from the medicine "Nocebo effect". The managerial implications are manifold for generic pharmaceutical industry as well as for pharmacists, physicians, and, finally government makers of communications policies for generic drugs
Toulemon, Léa. "Job quality, health insurance and the price of medical products : essays in applied economics." Thesis, Paris, Institut d'études politiques, 2016. http://www.theses.fr/2016IEPP0041/document.
Full textThis thesis focuses on two major aspects of individual well-being : job quality and the availability of medical care. We first investigate the long-term effects of job displacement on several dimensions of job quality. We use a coarsened exact matching method that takes into account time-invariant unobservables. Our main findings point to a deterioration of job quality after displacement. The magnitude and duration of the observed negative impact depends on the dimension considered. The second chapter studies the impact of a more generous public health insurance. We use the coexistence of two compulsory public health insurance systems in France, the national system, and the Alsace Moselle local system, which offers higher reimbursement rates. We investigate how moving to Alsace Moselle affects healthcare consumption, taking individuals who move between other French regions as a control group. Overall, we show that the Alsace Moselle local system does not increase healthcare consumption. The third chapter estimates the impact of group purchasing on medicine prices in French hospitals. We take advantage of the creation of regional purchasing groups between 2009 and 2014. We use a unique database that provides information on the average annual prices paid by public hospitals for all innovative medicines. Using a fixed effects model controlling for medicine-specific bargaining abilities of hospitals and medicine-specific price trends, we find that group purchasing reduces prices of medicines in oligopoly markets, but has no impact on prices of medicines for which there exist no competitors
Ngo, Nguene Marie Rosaire. "Les consommations de substances psychoactives sur le lieu de travail : le cas d’usagers et salariés des bars-restaurants et de chantiers du bâtiment parisiens." Thesis, Paris 10, 2020. http://www.theses.fr/2020PA100102.
Full textThis research aims to explain the relationship between the consumption of psychoactive products and professional environments, based on the differentiated forms of alcohol, tobacco, cocaine and cannabis use by Parisian employees of restaurants, bars and building sites. We are moving away from a purely quantitative measure of the consumption of psychoactive substances. We develop strictly sociological categories to consider these practices in and outside the workplace, by taking jointly into account: the organization of work, the management of the workforce, the working conditions themselves (for example night work in bars and restaurants, physical difficulties of work in building sites), the properties of the products consumed and their representations, as well as the social and professional characteristics of employees
Bouzillé, Guillaume. "Enjeux et place des data sciences dans le champ de la réutilisation secondaire des données massives cliniques : une approche basée sur des cas d’usage." Thesis, Rennes 1, 2019. http://www.theses.fr/2019REN1B023/document.
Full textThe dematerialization of health data, which started several years ago, now generates na huge amount of data produced by all actors of health. These data have the characteristics of being very heterogeneous and of being produced at different scales and in different domains. Their reuse in the context of clinical research, public health or patient care involves developing appropriate approaches based on methods from data science. The aim of this thesis is to evaluate, through three use cases, what are the current issues as well as the place of data sciences regarding the reuse of massive health data. To meet this objective, the first section exposes the characteristics of health big data and the technical aspects related to their reuse. The second section presents the organizational aspects for the exploitation and sharing of health big data. The third section describes the main methodological approaches in data sciences currently applied in the field of health. Finally, the fourth section illustrates, through three use cases, the contribution of these methods in the following fields: syndromic surveillance, pharmacovigilance and clinical research. Finally, we discuss the limits and challenges of data science in the context of health big data
Ouedraogo, Wendkouni Adelphe Sabine. "Étude comparée de l’intégration juridique de la tradimédecine dans les systèmes de santé publique en Afrique de l’Ouest : les cas du Ghana et du Burkina Faso." Thesis, Aix-Marseille, 2019. http://www.theses.fr/2019AIXM0009.
Full textTraditional medicine and pharmacopeia are still nowadays for thousands of people in West Africa, the unique healthcare solution. If this fact is often considered as arising solely from the weakness of the allopathic health system, it could also be a result of socio-cultural choices. Indeed, people especially in rural areas are strongly influenced by traditional vision and beliefs about diseases’ origins, which could have natural or induced causes in this traditional conception. For a long time, this resort to traditional medicine was done without the supervision and support of the appropriate measures and regulations. This has generated high public healthcare risks. Moreover, the multiplication of bioprospection’s without states control has led to a sharp increase in illicit appropriation of traditional medicine knowledge for the purposes of pharmaceutical innovation. This has created new issues in the South, especially about local populations’ intellectual property on their traditional knowledge. Highlighting these facts has raised new concerns within the competent international and regional institutions: the need of protection for local and indigenous communities’ rights over their genetic resources and associated tradimedical knowledge, and the need of building a fair system of exploitation of resources and medical indigenous knowledge for purposes of research and development. The Burkinabe and Ghanaian states have, in order to overcome these issues, adopted legislations to regulate traditional care practices as well as the production and placement on their national markets of traditional and neo-traditional medicines
Berger, Tristan. "L'accès aux informations environnementales et sanitaires : le cas des substances chimiques, des OGM et des médicaments." Thesis, Paris 1, 2020. http://www.theses.fr/2020PA01D006.
Full textThalidomide, asbestos, tobacco, PCB, benzene, valproate, dexfenfluramine, ECB, PIP implants, chlordecone, BPA, glyphosate, etc., there is now a long list of environmental and health risks that both affected risk management and undermined the public’s trust towards institutions. In this context, the issue of transparency related to environmental and health risks has continued to grow, not only for the purpose of directly informing citizens, but also for the purpose of building a counterexpertise, with a growing number of organizations or researchers seeking to review and check official expertise, and to challenge the action or the inertia of public authorities or companies. As a result, expert agencies increasingly receive requests to access environmental and health information, including to detailed datasets and techniques to test their reliability. Despite the progress that has characterized public rights to access information over the past forty years and the display of an open data policy, this thesis is based on the observation that access to information regimes are not effective. Going beyond the causes traditionally analyzed by doctrine (length of the delays, culture of secrecy, complexity), the thesis seeks to identify systemic limits to public access to environmental and health information. In particular, it highlights three sets of structural factors. First, the system for assessing product safety, entrusted to companies, inherently carries a risk of conflicts of interest and therefore undermines the reliability of the data to which the public is entitled. Second, the claim of intellectual property rights on data produced by companies, subjects them to a privatization process. Third, the lack of enforcement power of expert agencies, caught in a stranglehold between the exclusive rights of companies and the rights of public access. Three case studies – chemicals, GMOs and medicines – are used to highlight these structural limitations to access rights and, simultaneously, to deepen ecological and health democracy
Aïssaoui, Mohammed Amine. "Des modalités de fixation aux déterminants du prix des médicaments innovants : le cas des anticancéreux dans les pays de l’OCDE." Thesis, Paris Sciences et Lettres (ComUE), 2018. http://www.theses.fr/2018PSLED026.
Full textThis PhD thesis focused on the regulation and the determinants of innovative drugs prices in oncology. First, with a literature review we provided a comprehensive description examining the pricing mechanisms of innovative drugs in OECD countries. This approach shows us that most of the countries determine their prices according the assessment of the added value of the pharmaceutical product, and use HTA policies in their decisions making. Based on that conclusions and regarding the differences observed between the policies’ countries we assumed a framework to describe the pricing mechanism.In addition, we developed an original database which contains the anticancer drugs characteristics and their prices in 8 OECD countries. From empirical studies, we examined the relationship between the prices and the drugs characteristics. Before assessing prices disparities between the selected countries, we focused on the market approval of these medicines in each country. Nevertheless, even if most of the products were available in all studied countries, we observed differences between their regulations notably concerning the orphan status designation as well as for the time to market authorization.Thereafter, we achieved a comparative study to assess the discordance between the NICE and HAS. This analysis shows that despite a similar estimation of the added value, there is divergences between these HTA bodies in term of decisions making. Then, when we investigated the trends in prices across the selected countries, the level of pricing disparities observed, in most cases, seems to reflect the differences in pricing regulations.Finally, in order to highlight the determinants of these disparities between countries with respect to anticancer drug prices, we used the econometric approaches, we assessed both the effects on the prices of the added value (the incremental survival) and the pharmaceutical policy: It appears that the incremental survival impacts on the prices, independently of its uncertainties and its level of evidence provided in the clinical trials. In addition, the analysis confirms that the prices disparities reflect the pricing policy applied. Indeed, the countries using a free pricing policy have the highest-level prices, followed by the countries using the pricing negotiation and external reference pricing. Lastly, the countries using economic evaluation have the lowest prices
Leroy, Fanny. "Etude des délais de survenue des effets indésirables médicamenteux à partir des cas notifiés en pharmacovigilance : Problème de l'estimation d'une distribution en présence de données tronquées à droite." Phd thesis, Université Paris Sud - Paris XI, 2014. http://tel.archives-ouvertes.fr/tel-01011262.
Full textSantoro, Alice. "Métallothionéines et biomolécules capables de chélater et/ou de réduire le Cu et leur impact sur l'activité rédox et sur la stabilité des complexes de Cu d’intérêt médicinal : étude de cas sur des complexes de Cu-peptide amyloïde ou sur des principes actifs à base de Cu." Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAF067.
Full textDefects in copper (Cu) homeostasis have been linked to Alzheimer’s disease (AD) and Cancer. In AD, Cu has been found to bind to Aβ-peptides in extracellular amyloid-plaques, likely impacting the production of reactive oxygen species (ROS). Increased Cu levels have also been implicated in tumor growth. This has led to the development of Cu-based drugs. Particularly, the use of pro-oxidant Cu-complexes appears to be a promising strategy in cancer. Contrarily, in AD, redox silencing chelators are warranted. In a biological environment, the kinetic/thermodynamic stability of a Cu-complex against physiological competitors, is a key aspect to consider. In particular, the role of Cu-binding and reducing biomolecules (including metallothioneins, gluathione and cystein) is of pivotal importance. Within this context, this thesis aims to investigate the impact of these molecules on the redox-activity and stability of medicinal Cu-complexes. The studies carried out show that these molecules are key players for the fate of a Cu-complex, as they could lead to reactions of dissociation or transmetallation, abolishing the Cu-dependent ROS production
Beccaria, Kévin. "Evaluation de la diffusion intracérébrale des drogues antinéoplasiques après ouverture de la barrière hémato-encéphalique induite par ultrasons : Application aux gliomes malins de l’enfant Brainstem Blood-Brain Barrier Disruption and Enhanced Drug Delivery with an Unfocused Ultrasound Device – A Preclinical Study in Healthy and Tumor-Bearing Mice Ultrasound-Induced Blood-Brain Barrier Disruption for the Treatment of Gliomas and other Primary CNS Tumors Blood-Brain Barrier Disruption with Low-Intensity Pulsed Ultrasound for the Treatment of Pediatric Brain Tumors: A Review and Perspectives." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASS044.
Full textHigh-grade gliomas represent about 15% of pediatric brain tumors. No progress has been made in the treatment of these tumors during the last decades, and their prognosis remains dismal. The blood-brain barrier (BBB) plays a major role in the failure of medical treatments since it prevents most molecules to reach the brain, thus limiting the delivery of antineoplastic drugs to brain tumors. Disruption of the BBB (BBBD) with low intensity pulsed ultrasound in association with intravenous microbubbles is a technique that allows for safe, transient, and localized opening of the BBB. In this thesis, we confirmed the capacity of a new microbubble contrast agent to induce BBBD with ultrasound. We showed that opening of the BBB in the brainstem is possible with a nonfocused ultrasound device (SonoCloud®), in both healthy mice and a murine model of DIPG. We were able to increase irinotecan and panobinostat delivery in the brainstem of both healthy and tumor-bearing mice after BBBD, but we did not observe increased in overall survival. Preliminary studies have also been performed with checkpoints inhibitors and natural killer cells in a murine model of supra-tentorial high-grade glioma, but we were not able to increase survival in these models anymore. Finally, we prepared the first clinical trial that will evaluate the feasibility and tolerance of ultrasound-induced BBBD with the SonoCloud® device in the pediatric population. This trial will begin during the first semester of 2020